Our studies have uncovered BRD4 as a key vulnerability in NRAS‐mutant melanoma and demonstrate that co‐targeting BET and MEK could be a highly efficacious strategy to treat melanoma refractory to current therapies. Here, NRAS is linked to melanoma.